Evidence map›Paper›PMID 37490197›Full record

ArticleNeurochemical research2023

Neuroprotective Effects of Dammarane Sapogenins Against lipopolysaccharide-induced Cognitive Impairment, Neuroinflammation and Synaptic Dysfunction.

Liming Dong, Ning Jiang, Jie Bai, Yiman Li, Zhihui Song, Xinmin Liu, Chao Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Vascular Endothelial Protection Effects ofInternational journal of medical sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Liming DongDepartment of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Ning JiangResearch Center for Pharmacology & Toxicology, Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China.
Jie BaiDepartment of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Yiman LiDepartment of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Zhihui SongDepartment of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Xinmin LiuResearch Center for Pharmacology & Toxicology, Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China.
Chao ZhangDepartment of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China. laural.zhang@yahoo.com.
Capital Medical University · CNBeijing Tongren Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

Beijing Tongren Hospital, Capital Medical University 2020-YJJ-ZZL-050Bethune Public Welfare Foundation B-19-H-20200622Chinese Academy of Medical Sciences and Peking Union Medical College 2016-I2M-2-006
6 · The paper itself

Abstract

Neuroinflammation is a critical driver in the pathogenesis and progression of neurodegenerative disorders. Dammarane sapogenins (DS), a deglycosylated product of ginsenoside, possess a variety of potent biological activities. The present study aimed to explore the neuroprotective effects of DS in a rat model of neuroinflammation induced by intracerebroventricular injection of lipopolysaccharide (LPS). Our study revealed that DS pretreatment effectively improved LPS-induced associative learning and memory impairments in the active avoidance response test and spatial learning and memory in Morris water maze test. DS also remarkably inhibited LPS-induced neuroinflammation by suppressing microglia overactivation, pro-inflammatory cytok ine release (TNF-α and IL-1β) and reducing neuronal loss in the CA1 and DG regions of the hippocampus. Importantly, pretreatment with DS reversed LPS-induced upregulation of HMGB1 and TLR4 and inhibited their downstream NF-κB signaling activation, as evidenced by increased IκBα and decreased p-NF-κB p65 levels. Furthermore, DS ameliorated LPS-induced synaptic dysfunction by decreasing MMP-9 and increasing NMDAR1 expression in the hippocampus. Taken together, this study suggests that DS could be a promising treatment for preventing cognitive impairments caused by neuroinflammation.

Indexed as

Cognitive DysfunctionNeuroprotective AgentsSapogeninsAnimalsDammaranesHippocampusLipopolysaccharidesMicrogliaNeuroinflammatory DiseasesNF-kappa BRatsDammaranesLipopolysaccharidesNeuroprotective AgentsNF-kappa BSapogeninsCognitive impairmentDammarane sapogeninsLipopolysaccharideNeuroinflammationSynaptic dysfunction

Identifiers

PMID37490197
OpenAlexW4385230018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.